Literature DB >> 7688387

Immunodominance: a single amino acid substitution within an antigenic site alters intramolecular selection of T cell determinants.

Z Liu1, K P Williams, Y H Chang, J A Smith.   

Abstract

The mechanism of immunodominance was studied by mutating a single amino acid residue within an immunodominant determinant of Staphylococcus aureus nuclease (Nase). Residues 81 to 100, which can be further reduced to 86 to 100, were determined to be the immunodominant determinant of Nase in H-2k mice. By introducing selected single amino acid substitutions into the peptide encompassing residues 86 to 100 (p86-100), residue 90 was shown to be one of the critical amino acids for T cell recognition, inasmuch as most of the T cells recognizing p86-100 do not respond to a p86-100 analog with a substitution of leucine for alanine at the residue 90. A mutant of Nase with a replacement of alanine by leucine at residue 90 (A90L) was constructed, and for A90L region 112 to 130, which is a subdominant determinant in Nase, becomes immunodominant. Although unable to respond to Nase, T cells primed in vivo with the peptides covering various cryptic determinants proliferate when challenged with A90L in vitro. Our results suggest that at the protein level there is competition among potential T cell determinants of protein Ag for binding to MHC molecules, and that this competition plays a role in determining which determinant may become immunodominant.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688387

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  Understanding the focused CD4 T cell response to antigen and pathogenic organisms.

Authors:  Jason M Weaver; Andrea J Sant
Journal:  Immunol Res       Date:  2009-02-07       Impact factor: 2.829

2.  Immunodominance of CD4 T cells to foreign antigens is peptide intrinsic and independent of molecular context: implications for vaccine design.

Authors:  Jason M Weaver; Christopher A Lazarski; Katherine A Richards; Francisco A Chaves; Scott A Jenks; Paula R Menges; Andrea J Sant
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

3.  Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection.

Authors:  M C Jung; H M Diepolder; U Spengler; E A Wierenga; R Zachoval; R M Hoffmann; D Eichenlaub; G Frösner; H Will; G R Pape
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

4.  Class I MHC allochimeric presentation of composite immunogenic and self epitopes induces tolerance to genetically diverse rat strains.

Authors:  Natalya V Semiletova; Xiu-Da Shen; Daniel M Feldman; Feng Gao; Ana Mhoyan; Dhai Liu; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Rafik M Ghobrial
Journal:  Cell Immunol       Date:  2007-10-23       Impact factor: 4.868

5.  Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.

Authors:  Ronit Mazor; Jaime A Eberle; Xiaobo Hu; Aaron N Vassall; Masanori Onda; Richard Beers; Elizabeth C Lee; Robert J Kreitman; Byungkook Lee; David Baker; Chris King; Raffit Hassan; Itai Benhar; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 12.779

6.  Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.

Authors:  Ronit Mazor; Aaron N Vassall; Jaime A Eberle; Richard Beers; John E Weldon; David J Venzon; Kwong Y Tsang; Itai Benhar; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-03       Impact factor: 12.779

7.  Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.

Authors:  Ronit Mazor; Jingli Zhang; Laiman Xiang; Selamawit Addissie; Prince Awuah; Richard Beers; Raffit Hassan; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2015-10-06       Impact factor: 6.009

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.